SCHEMBL5832205

SCHEMBL5832205

CCCCCC(CO)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 2/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
OPRM1 P35372 1/20 0.41
CYP2D6 P10635 2/20 0.41
TP53 P04637 2/20 0.41
SPHK1 Q9NYA1 1/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CETP P11597 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28253004 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL10800419 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL10796538 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL27503911 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL5857227 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL28803871 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL9805659 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL27817187 0.98 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL282605 0.93 ALDH1A1 (0.44) LMNAMAPTMAPK1ALDH1A1CNR1
SCHEMBL10717521 0.87 ALDH1A1 (0.57) MAPTALDH1A1CNR1CNR2PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334211-B2 Hydrocracking catalyst, method for producing same, and method for producing hydroxy compound using said catalyst UBE INDUSTRIES, LTD. (JP) 2016-05-10 US disclosed
US-20140288335-A1 HYDROCRACKING CATALYST, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING HYDROXY COMPOUND USING SAID CATALYST UBE INDUSTRIES, LTD. (JP) 2014-09-25 US disclosed
US-7132092-B2 Metallized mesoporous silicate and method of oxidation with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-11-07 US disclosed
US-20050090688-A1 Metallized mesoporous silicate and method of oxidation with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-04-28 US disclosed
EP-1473275-A1 METALLIZED MESOPOROUS SILICATE AND METHOD OF OXIDATION WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed
US-4040977-A HALOACETAMIDE OR THIOCYANOACETAMIDE-ALCOHOL-FORMALDEHYDE CONDENSATES STERLING DRUG INC. (US) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288335-A1 HYDROCRACKING CATALYST, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING HYDROXY COMPOUND USING SAID CATALYST HAO2, HMOX1, HMOX2 LMNA 4218/4885MAPT 3600/4885MAPK1 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.